Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Down 49.3% in September

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the target of a large decline in short interest in September. As of September 30th, there was short interest totaling 3,800 shares, a decline of 49.3% from the September 15th total of 7,500 shares. Based on an average trading volume of 3,700 shares, the days-to-cover ratio is currently 1.0 days. Based on an average trading volume of 3,700 shares, the days-to-cover ratio is currently 1.0 days.

Clinuvel Pharmaceuticals Trading Down 0.4%

Shares of OTCMKTS CLVLY opened at $7.67 on Wednesday. The stock has a fifty day moving average price of $7.79 and a 200 day moving average price of $7.33. Clinuvel Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $9.79.

Clinuvel Pharmaceuticals Announces Dividend

The business also recently declared a dividend, which was paid on Monday, September 29th. Investors of record on Tuesday, September 9th were given a dividend of $0.0261 per share. The ex-dividend date of this dividend was Monday, September 8th. This represents a yield of 35.0%.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).